Welcome to our dedicated page for NPD news (Ticker: NPD), a resource for investors and traders seeking the latest updates and insights on NPD stock.
The news items associated with the ticker symbol NPD in the provided dataset do not report on Nepstar Corporation’s own operations or corporate events. Instead, NPD appears within Business Wire releases about ShangBay Capital and its Founding Managing Partner, William Dai. In these articles, Nepstar Corporation is cited as one of his prior Chief Financial Officer roles, described as "Nepstar Corporation (NYSE: NPD)".
As a result, the NPD news stream here functions as an indirect, historical reference rather than a direct feed of company-specific announcements. The coverage focuses on recognition of William Dai among GrowthCap’s Top 25 Healthcare Investors and outlines his background in corporate finance, mergers and acquisitions, and capital markets across Asia and the U.S. Within that context, NPD is mentioned alongside other companies where he previously served as CFO.
Users reviewing the NPD news page can therefore expect articles that provide biographical and career context for a finance executive whose history includes a CFO position at Nepstar Corporation. These pieces highlight his later work in healthcare-focused venture capital, not NPD’s own strategy, financial results, or products.
For investors or researchers, this page is most useful as a way to see how Nepstar Corporation is referenced in third-party news about former executives. To obtain news directly about NPD’s historical or current corporate actions, additional sources beyond the supplied material would be required.
William Dai, Founding Managing Partner at ShangBay Capital, has been named among GrowthCap's Top 25 Healthcare Investors for 2025, marking his third recognition on this prestigious list. Since founding ShangBay Capital in 2015, Dai has led the firm to invest in 72 portfolio companies with multiple successful exits, including Ceribell, one of the best recent Medtech IPOs. The firm has syndicated 26 portfolio companies with major strategics.
Dai currently serves on the boards of Luminopia, Aqua Medical, Meditrina, FemDx, and YorLabs. With over 20 years of experience in corporate finance, M&A, and capital markets, he previously held CFO positions at ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation, and Boston Scientific China.
ShangBay Capital's William Dai has been recognized among the top 25 healthcare investors for 2024 by GrowthCap. William Dai, the Founding Managing Partner at ShangBay Capital, has made significant contributions to the healthcare sector with a focus on medtech ventures. His expertise in corporate finance and mergers and acquisitions has led to the success of ShangBay Capital, nurturing 67 portfolio companies and achieving successful exits.
ShangBay Capital, a healthcare-focused venture capital firm, announces that William Dai has been recognized by GrowthCap as one of the top healthcare investors. This recognition highlights his significant contributions to advancing medical technologies. Since founding ShangBay in 2015, Dai has led investments in 55 portfolio companies, achieving multiple successful exits. His previous experience includes serving as CFO for several companies, including ShangPharma (NYSE: SHP) and Nepstar Corporation (NYSE: NPD). Dai emphasizes ShangBay's commitment to supporting entrepreneurs addressing unmet clinical needs.